![](https://investorshub.advfn.com/uicon/33511.png?cb=1696427377)
Monday, February 27, 2017 8:14:50 PM
their targeted assets...
Target Assets: SeD Biomed proposes to invest in one or more of the following biomedical assets described below and thereafter invest such biomedical assets into Amarantus.
Asset Name Description
1.Flavonoid Compound Composition for treating neurological disorders such as Alzheimer's Disease (Medical Food)
2.Clorinated Myrectin Shuts down kinases linked to cancer
3.Praesidium Natural mosquito repellent
4.Path-way Anti-Pathogenic Solution Broad spectrum antimicrobial compound
SeD Biomed currently has not acquired any of the abovementioned biomedical assets, the acquisition of which is still subject to negotiation, appropriate due diligence and the signing of definitive agreement(s).
*** mosquito repellent - really?
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM